Back to Journals » Clinical Ophthalmology » Volume 13

Central Serous Chorioretinopathy: Pathogenesis and Management

Authors Semeraro F, Morescalchi F, Russo A, Gambicorti E, Pilotto A, Parmeggiani F, Bartollino S, Costagliola C

Received 26 June 2019

Accepted for publication 21 October 2019

Published 2 December 2019 Volume 2019:13 Pages 2341—2352

DOI https://doi.org/10.2147/OPTH.S220845

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Nicola Ludin

Peer reviewer comments 2

Editor who approved publication: Dr Scott Fraser


Francesco Semeraro,1 Francesco Morescalchi,1 Andrea Russo,1 Elena Gambicorti,1 Andrea Pilotto,2 Francesco Parmeggiani,3 Silvia Bartollino,4 Ciro Costagliola4

1Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy; 2Department of Clinical and Experimental Sciences, Neurology Unit, University of Brescia, Brescia, Italy; 3Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy; 4Department of Medicine and Health Science “V. Tiberio”, University of Molise, Campobasso, Italy

Correspondence: Silvia Bartollino
Department of Medicine and Health Science “V. Tiberio”, University of Molise, Via de Santis, Campobasso 86100, Italy
Email silvia.bartollino@unimol.it

Abstract: Central serous chorioretinopathy (CSC) is a common retina disease and has a relative high recurrence rate, etiology, and pathogenesis of which remains largely ambiguous. The effects on the retina are usually self-limited, although some people are left with permanent vision loss due to progressive and irreversible photoreceptor damage or retinal pigment epithelium atrophy. There have been a number of interventions used in CSC, including, but not limited to, laser treatment, photodynamic therapy (PDT), intravitreal injection of anti-vascular endothelial growth factor agents, and subthreshold lasers. It is not clear whether there is a clinically important benefit to treating acute CSC, which often resolves spontaneously as part of its natural history. Of the interventions studied to date, PDT and micropulse laser treatment appear the most promising. 

Keywords: central serous chorioretinopathy, acute central serous chorioretinopathy, chronic central serous chorioretinopathy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]